A Paradiso

Summary

Affiliation: National Cancer Institute
Country: Italy

Publications

  1. pmc Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
    Jie Sheng Chu
    The Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing 100071, People s Republic of China
    J Exp Clin Cancer Res 32:16. 2013
  2. pmc Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis
    Andrea Malfettone
    Functional Biomorphology Laboratory, National Cancer Centre, Bari, Italy
    BMC Cancer 12:106. 2012
  3. pmc Comparison of data-merging methods with SVM attribute selection and classification in breast cancer gene expression
    Vitoantonio Bevilacqua
    Department of Electrical and Electronics, Polytechnic of Bari, Via E, Orabona, 4, 70125 Bari, Italy
    BMC Bioinformatics 13:S9. 2012
  4. pmc "Sequencing-grade" screening for BRCA1 variants by oligo-arrays
    Alessandro Monaco
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
    J Transl Med 6:64. 2008
  5. pmc Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers
    Christina Yau
    Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA
    Breast Cancer Res 9:R59. 2007
  6. pmc Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer
    Jian Ming Xu
    Beijing 307 Hospital Cancer Center, Beijing, China
    BMC Cancer 6:288. 2006
  7. pmc Developing optimal input design strategies in cancer systems biology with applications to microfluidic device engineering
    Filippo Menolascina
    Department of Electrical Engineering and Electronics, Technical University of Bari, Via E Orabona 4, Bari, Italy
    BMC Bioinformatics 10:S4. 2009
  8. ncbi request reprint Phosphatidylinositol 3-kinase in breast cancer: where from here?
    Angelo Paradiso
    Clinical Experimental Oncology Laboratory, National Cancer Institute, Bari, Italy
    Clin Cancer Res 13:5988-90. 2007
  9. ncbi request reprint Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer
    A Paradiso
    Clinical Experimental Oncology Laboratory, National Cancer Institute, Via Amendola 209, 70125 Bari, Italy
    Ann Oncol 16:iv14-19. 2005
  10. ncbi request reprint The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis
    Angelo Paradiso
    National Cancer Institute Giovanni Paolo II, Bari, Italy
    Int J Biol Markers 24:119-29. 2009

Detail Information

Publications56

  1. pmc Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
    Jie Sheng Chu
    The Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing 100071, People s Republic of China
    J Exp Clin Cancer Res 32:16. 2013
    ..We explore the clinical and prognostic significance of expression of vascular endothelial growth factor receptor (VEGFR)-2, platelet-derived growth factor receptor (PDGFR)-β, and c-Met in patients with hepatocellular carcinoma (HCC)...
  2. pmc Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis
    Andrea Malfettone
    Functional Biomorphology Laboratory, National Cancer Centre, Bari, Italy
    BMC Cancer 12:106. 2012
    ..The aim of this study was to best characterize tumors scored as grade 2...
  3. pmc Comparison of data-merging methods with SVM attribute selection and classification in breast cancer gene expression
    Vitoantonio Bevilacqua
    Department of Electrical and Electronics, Polytechnic of Bari, Via E, Orabona, 4, 70125 Bari, Italy
    BMC Bioinformatics 13:S9. 2012
    ..It is therefore of great interest to integrate different studies, thus increasing sample size...
  4. pmc "Sequencing-grade" screening for BRCA1 variants by oligo-arrays
    Alessandro Monaco
    Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
    J Transl Med 6:64. 2008
    ..This system is particularly useful for the screening of long genomic regions with relatively infrequent but clinically relevant variants, while drastically cutting time and costs in comparison to high-throughput sequencing...
  5. pmc Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers
    Christina Yau
    Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA
    Breast Cancer Res 9:R59. 2007
    ..Except for inherited forms of breast cancer, however, there is little genetic or epigenetic understanding of the biological basis linking aging with sporadic breast cancer incidence and its clinical behavior...
  6. pmc Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer
    Jian Ming Xu
    Beijing 307 Hospital Cancer Center, Beijing, China
    BMC Cancer 6:288. 2006
    ....
  7. pmc Developing optimal input design strategies in cancer systems biology with applications to microfluidic device engineering
    Filippo Menolascina
    Department of Electrical Engineering and Electronics, Technical University of Bari, Via E Orabona 4, Bari, Italy
    BMC Bioinformatics 10:S4. 2009
    ..Optimisation of the input time-profile, however, still remains a major area of research due to the complexity of the problem and its relevance for the task of information retrieval in systems biology-related experiments...
  8. ncbi request reprint Phosphatidylinositol 3-kinase in breast cancer: where from here?
    Angelo Paradiso
    Clinical Experimental Oncology Laboratory, National Cancer Institute, Bari, Italy
    Clin Cancer Res 13:5988-90. 2007
  9. ncbi request reprint Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer
    A Paradiso
    Clinical Experimental Oncology Laboratory, National Cancer Institute, Via Amendola 209, 70125 Bari, Italy
    Ann Oncol 16:iv14-19. 2005
    ....
  10. ncbi request reprint The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis
    Angelo Paradiso
    National Cancer Institute Giovanni Paolo II, Bari, Italy
    Int J Biol Markers 24:119-29. 2009
    ..During this meeting, methodological aspects, scientific programs and preliminary results were presented and discussed...
  11. ncbi request reprint Familial breast cancer screening: ethical and social implications
    A Paradiso
    Clinical Experimental Oncology Laboratory, National Cancer Institute, Bari, Italy
    Ann Oncol 15:I5-I6. 2004
  12. doi request reprint Hereditary breast cancer: clinical features and risk reduction strategies
    A Paradiso
    Scientific Direction, National Cancer Center, Istituto Tumori Giovanni Paolo II, Bari, Italy
    Ann Oncol 22:i31-6. 2011
    ..These may also deepen our knowledge on possible differences in the likelihood of clinical benefit to be expected among BRCA1- and BRCA2-altered tumours...
  13. ncbi request reprint Failure of primary breast cancer neoangiogenesis to predict pattern of distant metastasis
    A Paradiso
    Clinical Experimental Oncology Laboratory, National Cancer Institute, Bari, Italy
    Clin Exp Med 1:127-32. 2001
    ..98-3.35, P<0.06) by multivariate analysis. In conclusion, the assessment of neoangiogenesis of primary breast cancer by CD34 expression does not provide information predictive of different distant sites of metastasis...
  14. pmc Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer
    A Paradiso
    Clinical Experimental Oncology Laboratory, Oncology Institute, Bari, Italy
    Br J Cancer 84:651-8. 2001
    ....
  15. ncbi request reprint BRCA1 expression and molecular alterations in familial breast cancer
    A Mangia
    Clinical Experimental Oncology Laboratory, National Cancer Institute Bari, Italy
    Histol Histopathol 24:69-76. 2009
    ..029). The frequency of MS110 negative cases also detected in BRCA1-wild type tumours, points to the inability of the BRCA1 IHC expression in discriminating between familial and sporadic breast cancer...
  16. ncbi request reprint Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer
    A Paradiso
    Clinical Experimental Oncology Laboratory, Senology Unit, Histopathology Service, and Medical Oncology Unit, National Oncology Institute, Bari, Italy
    J Clin Oncol 19:3929-37. 2001
    ..The aim of the present study was to investigate whether patients with fast-proliferating, node-negative breast cancer could benefit from adjuvant chemotherapy with fluorouracil, epirubicin, and cyclophosphamide (FEC)...
  17. ncbi request reprint Mammography and morphobiologic characteristics of human breast cancer
    A Paradiso
    Experimental and Clinical Oncology Laboratory, Oncology Institute, Bari, Italy
    Tumori 79:422-6. 1993
    ..CONCLUSIONS: Certain relationships between mammographic features and biologic characteristics could be of potential clinical interest and stimulate more detailed studies on this issue...
  18. doi request reprint Proteomic profile in familial breast cancer patients
    V M Garrisi
    Department of Experimental Oncology, National Cancer Research Centre, Istituto Tumori Giovanni Paolo II, Bari, Italy
    Clin Biochem 46:259-65. 2013
    ..New diagnostic tools useful for breast cancer management are urgently needed. The aim of the present paper is to look for new candidate tumor markers useful for diagnosis in these patients...
  19. pmc Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer
    K Danza
    Molecular Genetic Laboratory, National Cancer Research Centre, Istituto Tumori Giovanni Paolo II, Bari, Italy
    Eur J Hum Genet 21:824-30. 2013
    ..58; P=0.008) and in TNBC (r=0.62; P=0.007). The higher levels of Ang-1, Ang-2 and VEGF mRNA found in BRCA carriers and TNBCs suggest that they could be attractive angiogenic therapeutic targets in these breast cancers. ..
  20. pmc Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer
    A Azzariti
    Clinical Experimental Oncology Laboratory, National Cancer Institute, Via Hahnemann 10, Bari 70126, Italy
    Br J Cancer 104:769-80. 2011
    ..Preclinical evaluation of AZD1152 has been reported in several human cancer models. The potentiality of this compound in combination therapy warrants further investigation in solid tumours...
  21. ncbi request reprint Attitude towards genetic testing for breast cancer susceptibility: a comparison of affected and unaffected women
    M Bruno
    Experimental Oncology Department, Cancer Institute of Bari, Bari, Italy
    Eur J Cancer Care (Engl) 19:360-8. 2010
    ..These results provide important indications for the development of educational strategies...
  22. ncbi request reprint GnRH receptors in human breast cancer and its contiguous not-involved breast tissue
    A Paradiso
    Laboratorio Oncologia Sperimentale Clinica, IRCCS Ospedale Oncologico, Bari, Italy
    J Endocrinol Invest 23:90-6. 2000
    ..05). The GnRH receptors status of primary tumor and contiguous not-involved breast tissue resulted associated (overall agreement: 63%, p<0.05) but no specific steroid patterns for GnRH-R positivity was observed...
  23. ncbi request reprint Predictability of monthly and yearly rhythms of breast cancer features
    A Paradiso
    Clinical Experimental Oncology Laboratory, National Oncology Institute of Bari, Italy
    Breast Cancer Res Treat 67:41-9. 2001
    ..We confirmed that breast biology has significant menstrual and seasonal variations and that the seasonality is probably the timing factor more relevant in periodicity determination...
  24. ncbi request reprint Different assays for HER-2/neu evaluation in breast cancer
    S Tommasi
    Clinical Experimental Oncology Laboratory, Oncology Institute, Bari, Italy
    Tumori 78:106-10. 1992
    ..Immunohistochemical evaluations were more in accord with immunoprecipitation data when performed on frozen or Bouin-fixed, paraffin-embedded tissues than on formalin-fixed, paraffin-embedded tissues...
  25. ncbi request reprint Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors
    L Porcelli
    Clinical Experimental Oncology Laboratory, National Cancer Institute Giovanni Paolo II, Viale O Flacco, 65, 70124 Bari, Italy
    Curr Pharm Des 19:918-26. 2013
    ....
  26. ncbi request reprint Synthetic lethality to overcome cancer drug resistance
    L Porcelli
    Clinical Experimental Oncology Laboratory, National Cancer Institute Giovanni Paolo II, Bari, Italy
    Curr Med Chem 19:3858-73. 2012
    ..In addition, new molecularly targeted strategies to overcome drug resistance are suggested...
  27. ncbi request reprint Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer
    A Daniele
    Department of Experimental Oncology, Laboratory of Analyses, Institute of Oncology, Via Hannhemann 10, Bari, Italy
    Anticancer Res 30:3521-7. 2010
    ..3 levels, and MMP-9 and grading. This study suggests a clinical utility of these proteolytic markers in malignant tumour, growth, invasion and metastasis in breast cancer...
  28. ncbi request reprint Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells
    S Sebastian
    Clinical Experimental Oncology Laboratory, National Cancer Institute, Bari, Italy
    Int J Mol Med 21:809-17. 2008
    ..Our results confirmed the in vitro efficacy of an anti-EGFR approach, but other targets than those analysed here should be characterised in order to identify valid predictive factors for gefitinib utilisation...
  29. pmc Nuclear NHERF1 expression as a prognostic marker in breast cancer
    A Paradiso
    Experimental Medical Oncology, NCRC Istituto Tumori Giovanni Paolo II, Bari, Italy
    Cell Death Dis 4:e904. 2013
    ....
  30. ncbi request reprint Short- and long-term effects of a training session on pathologists' performance: the INQAT experience for histological grading in breast cancer
    A Paradiso
    Italian Network for Quality Assessment of Tumour Biomarkers, National Cancer Institute, Bari, Italy
    J Clin Pathol 62:279-81. 2009
    ....
  31. ncbi request reprint Awareness of breast cancer genetics and interest in predictive genetic testing: a survey of a southern Italian population
    M Bruno
    National Cancer Institute, Bari, Italy
    Ann Oncol 15:I48-I54. 2004
    ....
  32. ncbi request reprint MUC3 and MCA serum levels and steroid receptor content in breast cancer
    M Quaranta
    Chemical Clinical Microbiology and Immunology Laboratory Unit, Department of Experimental Oncology, National Oncology Institute, Bari, Italy
    Int J Biol Markers 19:109-14. 2004
    ..Our results suggest that further investigations are necessary to establish whether progesterone can modulate MUC3 and MCA expression in breast cancer...
  33. pmc Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer
    S De Summa
    Molecular Genetics Laboratory, National Cancer Research Centre, Istituto Tumori Giovanni Paolo II, Bari, Italy
    Cell Death Dis 5:e1076. 2014
    ..PARP1 and miR17 could therefore be further investigated as molecular biomarkers of 'BRCAness' phenotype, indicating patients which could really benefit from PARP inhibitor therapies. ..
  34. ncbi request reprint Solitary plasmacytoma of bone and extramedullary plasmacytoma: two different nosological entities?
    M Guida
    Medical Oncology Division, Oncology Institute, Bari, Italy
    Tumori 80:370-7. 1994
    ..Indicators of disease activity and extension, and of a possible evolution to multiple myeloma, have not been identified as yet...
  35. ncbi request reprint Sequential alternate administration of tamoxifen and medroxyprogesterone acetate in advanced breast cancer: clinical-biological randomized study
    M De Lena
    Oncology Division, Oncology Institute, Bari, Italy
    Tumori 76:190-5. 1990
    ..In conclusion, our study demonstrated that while the manipulation of hormone receptors seems possible, results indicating better overall survival and time to progression were not obtained with alternate sequential TAM-MPA therapy...
  36. doi request reprint Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib
    V M Garrisi
    IRCCS National Cancer Centre Giovanni Paolo II, Department of Experimental Oncology, Bari, Italy
    Clin Biochem 44:936-40. 2011
    ....
  37. ncbi request reprint Primary tumours neoangiogenesis and P53 expression in oral carcinoma patients
    L Grammatica
    Otorhinolaryngology Unit, National Cancer Institute, Bari, Italy
    J Exp Clin Cancer Res 20:225-30. 2001
    ..R.=2.7; 95% C.I. 1.09-6.9), while p53 status only approached the statistical significance (O.R.=2.5; 95% C.I. 0.96-6.5; p=0.06)...
  38. ncbi request reprint Immunoglobulin heavy chain gene rearrangement in B-cell non-Hodgkin's lymphomas detected by the polymerase chain reaction
    M Alaibac
    Experimental and Clinical Oncology Laboratory, Oncology Institute, Bari, Italy
    Tumori 81:128-31. 1995
    ....
  39. ncbi request reprint BRCAness: a deeper insight into basal-like breast tumors
    S De Summa
    NCRC Istituto Tumori Giovanni Paolo II, Bari, Italy
    Ann Oncol 24:viii13-viii21. 2013
    ....
  40. ncbi request reprint M-VECA (methotrexate, vinblastine, epidoxorubicin and carboplatin) in the treatment of advanced urothelial carcinoma
    V Lorusso
    Medical Oncology Division, Oncology Institute, Bari, Italy
    Tumori 79:191-4. 1993
    ..However, the possibility of substituting carboplatin for cisplatin as neoadjuvant therapy for less advanced stages needs further investigation in randomized studies...
  41. ncbi request reprint Mutations spanning P53 exons 5-9 detected by non-isotopic RNAse cleavage assay and protein expression in human colon cancer
    S Tommasi
    National Cancer Institute, Experimental Clinical Oncology Laboratory, Via Amendola, 209-70126 Bari, Italy
    Cancer Genet Cytogenet 129:40-2. 2001
    ..Our experience showed NIRCA to be fast, reliable and providing the ability to study long target regions in a single step, thus making this assay useful for genetic screenings...
  42. ncbi request reprint Metastatic site and p53 primary tumor expression in previously untreated stage IV breast cancer patients
    A Paradiso
    Oncology Institute of Bari, Italy
    Anticancer Res 19:4523-8. 1999
    ....
  43. ncbi request reprint A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies
    G Ranieri
    Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Institute Giovanni Paolo II of Bari, Bari, Italy
    Crit Rev Oncol Hematol 88:187-97. 2013
    ..In this review article, we will analyze biological data from dog tumors and comparative features with human tumors, and new therapeutic approaches translated from dog to human cancer. ..
  44. doi request reprint Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity
    L Porcelli
    Laboratorio di Oncologia Sperimentale Clinica, Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy
    J Med Chem 55:37-54. 2012
    ..Finally, the capability of R-1 and S-1 to inhibit cellular proliferation in colon cancer cell lines was also evaluated...
  45. ncbi request reprint Breast cancer: biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets
    E Guastamacchia
    Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy
    Curr Drug Targets Immune Endocr Metabol Disord 3:205-9. 2003
    ..We set out to investigate the effect of diabetes mellitus on the expression of estrogen and progesteron receptors and on the proliferative activity of primary breast cancer...
  46. pmc Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients
    A Paradiso
    Clinical Experimental Oncology Laboratory, Oncology Institute, Bari, Italy
    Br J Cancer 82:560-7. 2000
    ..89; 95% CI 2.85-1.26; two-sided P < 0.03). Our study suggests that immunohistochemical expression of p53 and TS could assist the clinician in predicting response of colorectal cancer patients to modulated MTX-5-FU therapy...
  47. pmc Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells
    G Giannelli
    Section of Internal Medicine, Department of Internal Medicine, Immunology, and Infectious Diseases, University of Bari Medical School, Bari, Italy
    Br J Cancer 91:1964-9. 2004
    ..As patients with HCC have different Ln-5 expression levels, these results may help to better understand which patients might benefit from gefitinib treatment...
  48. ncbi request reprint Quality control for biomarker determination in oncology: the experience of the Italian Network for Quality Assessment of Tumor Biomarkers (INQAT)
    A Paradiso
    Clinical Experimental Oncology Laboratory, National Cancer Institute of Bari, Italy
    Int J Biol Markers 17:201-14. 2002
    ....
  49. ncbi request reprint Molecular pathways and related target therapies in liver carcinoma
    S Tommasi
    Clinical Experimental Oncology Laboratory, National Cancer Institute Giovanni Paolo II Bari, Italy
    Curr Pharm Des 13:3279-87. 2007
    ..This scenario opens new avenues for the prevention and the treatment of HCC. In the present review the main metabolic pathways and molecular alterations have been described together with recent advances in molecular and gene therapy...
  50. ncbi request reprint mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer
    A Paradiso
    Clinical Experimental Oncology Laboratory, Oncology Institute, Bari, Italy
    Oncology 62:278-85. 2002
    ..We investigated the relevance of mdm2 and p53 primary tumour expression to the clinical outcome of a consecutive series of advanced colorectal cancer patients treated with a 5-fluorouracil-based chemotherapy...
  51. ncbi request reprint Intravenous administration of cyclophosphamide, methotrexate and 5-fluorouracil in metastatic breast cancer. A pilot study
    M De Lena
    Oncologic Institute, Bari, Italia
    Tumori 74:57-63. 1988
    ..o. Nausea and vomiting, in particular, were limited to 24-48 h after administration of the drugs, and alopecia was seldom observed...
  52. ncbi request reprint Interobserver reproducibility in diagnosis of breast lesions. A panel in Puglia (Italy). GSBioCaM
    C Giardina
    Istituto di Anatomia Patologica, , Italy
    Tumori 84:354-9. 1998
    ..Moreover, the study confirmed the diagnostic difficulties for borderline lesions and the necessity of further investigation for sclerosing lesions with discordant diagnoses...
  53. pmc A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer
    S De Placido
    Department Molecular and Clinical Oncology and Endocrinology, University Federico II, Via S Pansini 5, Napoli 80131, Italy
    Br J Cancer 92:467-74. 2005
    ..74; 95% CI: 0.555-0.987; P=0.040), with a nonsignificant improvement of OS (HR=0.84; 95% CI: 0.54-1.32). A --> CMF is superior to CMF. Adding GT after chemotherapy is beneficial for premenopausal node-positive patients...
  54. ncbi request reprint The impact of body mass index and type 2 diabetes on breast cancer: current therapeutic measures of prevention
    F Resta
    Section of Geriatrics and Gerontology, Department of Internal Medicine, Immunology and Infectious Disease, University of Bari, Italy
    Curr Drug Targets Immune Endocr Metabol Disord 4:327-33. 2004
    ..9 was found (p<0.01). In the Apulian population, the presence of both type 2 diabetes and elevated values of BMI (that is in a condition of hyperinsulinemia) were found to enhance the frequency of breast cancer...
  55. ncbi request reprint Neoadjuvant chemotherapy in inoperable, locally advanced, and inflammatory breast carcinoma: a pilot study of MTT assay in vitro and outcome analysis of 10 patients
    J M Xu
    Beijing 307 Hospital Cancer Center, Beijing, China
    Am J Clin Oncol 24:259-63. 2001
    ..Compared with conventional chemotherapy, the clinical response and long-term results seem to be more encouraging...
  56. ncbi request reprint Genetic alterations in hereditary breast cancer
    G Cipollini
    Section of Onco Genetics, Division of Surgical, Molecular and Ultrastructural Pathology, Department of Oncology, University of Pisa and University Hospital of Pisa, Pisa, Italy
    Ann Oncol 15:I7-I13. 2004
    ..The presence of founder mutations has practical implications for genetic testing...